Oculus Innovative Sciences Announces Licensing Agreement
Oculus Innovative Sciences, Inc. recently announced the exclusive licensing of the company’s Microcyn-based human healthcare products in
“Since our founding in 2007, More Pharma has established a track record of strong growth because of our ability to identify and partner with cutting-edge pharmaceutical technologies,” said Guillermo Ibarra, More Pharma’s CEO. “We believe the Microcyn Technology – already proven and with a dominant share of the Mexican market – is a compelling addition to our product portfolio, allowing us to build upon Oculus’ established success in the Mexican market and affording us the opportunity to achieve similar commercial success throughout the South and Central American and Caribbean countries.”
Under the terms of the agreement, More Pharma will pay Oculus an up-front $5.1-million licensing fee. The transition of the marketing and sales effort in
“We are excited about partnering with More Pharma and their rapidly growing sales and marketing teams in Mexico, the Caribbean, Central, and South America,” added Hoji Alimi, CEO of Oculus. “We believe this positions us for accelerated long-term unit sales growth in
Founded in 2007, More Pharma is a pharmaceutical company with strong growth performance and a team of more than 300 people. The company has a talented sales and marketing team with significant prior experience with large international pharmaceutical companies. For more information, visit www.morepharmacorp.com.
Oculus Innovative Sciences is a commercial healthcare company that designs, produces, and markets innovative, safe, and effective healthcare products. Oculus is pioneering innovative solutions in multiple markets, including dermatology, oral care, surgical, wound care, animal healthcare, and others and has commercialized products in the US, Europe, India, China, and Mexico and select Middle East countries. For more information, visit www.oculusis.com.
Total Page Views: 1586
